Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This Baryy has now thirty days to sell his 41,131,212 shares for which he paid + 300.000 dollars. He/she doesn't have to sell these shares, but if he want to, the only restriction is that the avarage share price for 5 consecutive days needs to be above 0.050 dollar/share. In this way the share price won't be negatively affected.
So:
1) The company gets +300.000 dollar extra working capital which is good
2) if Barry decides to hold his shares for the next 30 days we have a big shareholder at our side (like the institutional investor)
3) if he sells, the share price won't be affected because in the period when he is selling the avarage 5-days share price cannot go under 0.05 dollar/share
IMO this is good news!
dividend in shares LOL and afterwarts a R/S
Well, we all know we will never be able to convince you. But hey, it doesn't bother me.
If they can remain Mondays' volume for another couple of days, we could speak of more and more exposure.
Very interesting, certainly because of the three conferences (LSI and the 2 military conferences) which are taking off on 10 August and some days later.
CTSO: 2military conferences and 1 other conference coming on 10-11 Aug, 16-19 Aug and 11 Aug.
My stock for next week: CytoSorbents Corporation CTSO.ob
GLTA
If they can get the financing done, I still believe there is a future for EVFN. The debts are paid.
Three possibilities:
1) bankrupt
2) another R/S
3) 10 to 100-bagger as a start and maybe someday above the dollar
A conferences' reputation depends on who is speaking. If the reputation is low, no company wants to enter (and pay). If the reputation is high, it is an honour to enter (and pay more).
Whether or not the company has to pay to give a presentation, the two military conferences + the LSI conference in August and the 3 East Medical Device Conference in June , prove that CTSO has a good reputation towards the medical industry and doctors with an exciting, solid product. If they wouldn't have that, they wouldn't be allowed to enter the conferences.
Great news for shorts, bad news for longs.
IMO this will be around 0.05 - 0.10 again in less than two months.
"A letter of intent and the buyers name remains confidential..."
How many times have I heard that same line...? Are there still people who believe that? And don't forget the Safe Harbor Statement.
It's a bad strategy and it often means dilution time instead of money time.
99% short!!! Well I hope the BOD can do some magic.
When this company wouldn't have that much potential, it wouldn't be invited to speak in front of all these conferences.
Potential = speaking in front of conferences = potential exposure toward institutional buyers = $$$
CTSO device could treat bioattack victims
"The head of CytoSorbents announced on July 26 that he expects the company's CytoSorb blood purification device and other resins to treat victims of weapons of mass destruction, including biological or chemical attacks.
Dr. Phillip Chan, president and CEO of CytoSorbents, expects that support for the company's technology and products from the Department of Defense will increase the number of applications they can be used for, including the treatment of victims exposed to dangerous toxic agents.
“Blood purification using CytoSorb or other resins under development may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare,” Dr. Chan said.
..."
http://www.bioprepwatch.com/news/214360-blood-purification-device-could-treat-bioattack-victims
Very interesting CSKH blog: http://solarstockinvestor.com/solar-stocks/clear-skies-solar-cskh-penny-stock/
CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.
The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses' premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.
"Dr. Phillip Chan, Chief Executive Officer and President, commented, "Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients."
Dr. Chan continued, "We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of 'supportive care and watchful waiting' to one of 'active treatment,' potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products."
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=32644040&topic=CTSO&symbology=null&cp=off&webmasterId=94743
G-R-E-A-T
+ 11 August LSI presentation!!!
CTSO to present at LSI conference 11Aug 2010:
25+ Emerging Medical Technology CEOs to Present Their Opportunities Online August 11, 2010, Hosted by Life Science Intelligence
Companies on the August 11th program include: Aespira, CerMed, CritiSense, CytoSorbents, Genomic Expression, Headway, ImmunoChemistry Technologies, Intellewave, IVDiagnostics, Magellan Spine Technologies, Micronics, NuOrtho Surgical, Omniflo, Omnivus, OrthoAccel Technologies, Pluristem Therapeutics , Pro-IV Medical, Redi-Tech Medical Products, Silere Medical Technology, SMT R&D, SpineSmith, Stellarray, TechniScan Medical Systems, TonoGuard, and VasoNova.
http://www.financialpost.com/markets/news/Emerging+Medical+Technology+CEOs+Present+Their+Opportunities+Online+August+2010+Hosted+Life+Science+Intelligence/3250784/story.html
LSI’s Emerging Medical Technologies Spotlight is a travel-free online conference, which serves as a convenient forum for medical technology innovators, investors, and dealmakers to connect and collaborate from their desktops. Registered attendees and select LSI members, which include the top medtech dealmaking companies and investment firms, will have an opportunity to quickly and efficiently preview these innovative companies and then selectively network with the CEOs.
I like their financials posted on pinksheets.com regarding the previous period:
Total assets: +21M dollar!
Total assets > total liabililities: +21M > 19M
Total stockholders equity is POSITIVE! : +/- 3M dollar
Net income is POSITIVE: pro forma: 550,280 dollar
Income per share is POSITIVE: 0.004 dollar
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7206448
are they that stupid?
Moderator can you sticky this post temporarily?
RT - 13,04% PPS: 0.006
I feel sorry for the ones who got in, but I warned you.
L1: Bid 0.086 Bid Size 5000
Ask 0.09 Ask Size 50
http://www.vantagewire.com/quotes/viewquote/CTSO/
There are almost no sellers. In fact the bid volume at 0.088 is 100x higher (5000) than the ask volume at 0.090 (50) according to vantagewire.com from which I have live information. As I can see now, the next MM at the ask is sitting on 0.11 dollar/share. So a lot of space to move up.
CTSO is getting more and more exposure to important investors like the In3 East Medical Device Conference and the LSI conference coming up on 11 Aug.
CTSO will get more and more exposure because of these seminars and conferences. Like the LSI conference on 11 August 2010 (see my previous underlined post)
Patient enrollment is coming closer to its' 100th patient every day that passes.
When CTSO receives CE mark approval we're talking about a +1 dollarstock instead. And even then I won't sell, their pipeline is immense and their technology groundbreaking.
CTSO to present at LSI conference 11Aug 2010:
25+ Emerging Medical Technology CEOs to Present Their Opportunities Online August 11, 2010, Hosted by Life Science Intelligence
Companies on the August 11th program include: Aespira, CerMed, CritiSense, CytoSorbents, Genomic Expression, Headway, ImmunoChemistry Technologies, Intellewave, IVDiagnostics, Magellan Spine Technologies, Micronics, NuOrtho Surgical, Omniflo, Omnivus, OrthoAccel Technologies, Pluristem Therapeutics , Pro-IV Medical, Redi-Tech Medical Products, Silere Medical Technology, SMT R&D, SpineSmith, Stellarray, TechniScan Medical Systems, TonoGuard, and VasoNova.
http://www.financialpost.com/markets/news/Emerging+Medical+Technology+CEOs+Present+Their+Opportunities+Online+August+2010+Hosted+Life+Science+Intelligence/3250784/story.html
LSI’s Emerging Medical Technologies Spotlight is a travel-free online conference, which serves as a convenient forum for medical technology innovators, investors, and dealmakers to connect and collaborate from their desktops. Registered attendees and select LSI members, which include the top medtech dealmaking companies and investment firms, will have an opportunity to quickly and efficiently preview these innovative companies and then selectively network with the CEOs.
That is our only hope and makes me stay in.
I got out. What a scam!!! I'm happy I only had 100.000 shares. That's the risk of pinksheets, maybe I'm lucky I only lost 300 dollar with this scam. I hope Cataldo will go to jail.
Let's say:(more than) 5000 dollar x (more than) 20 business days = 100.000 dollar
That would be a nice position, meaning 1million shares for an institution as a start-up position in CTSO.
IMO one or more institutions are buying themselves a comfortable position into CTSO.
Price: 0.09 dollar/share
Market makers: UBS Securities LLC (bid and ask), Archipelago Trading Services Inc (bid), The Vertical Trading Group LLC (ask)
I will buy more if it goes below .0015
That was was happened. Not their fault but KPMG's mistake.
You should read the PR and KarinCA his post. It says it wasn't amst their fault.
Great day today.
We come closser to the enrollment of patient number 80 and finally of patient number 100.
Every day that passes the probability that the share price breaks .10$/share gets bigger, because of new buyers holding their shares with them for the long term and because of possible institutions buying a position into ctso.
Remember this:
keywords:
1° limited competition (only Xigris is approved to treat sepsis, but has questionable efficacy and safety)
2°critical care play and therefore an easy market penetration
3° reimbursement friendly
high margin disposable device in an under-served multi-billion dollar market with strategically important technology
The Company has leading, patented technology backed by strong science and a highly profitable business model. We believe CytoSorb™ has the potential to be a blockbuster therapy that can be sold throughout the world as a treatment for sepsis and other diseases exacerbated by cytokine storm. If successful, these characteristics position the Company well for growth and future value creation for shareholders. Also, we continue to unlock the value of our underlying polymer platform technology through the ability to modify it for other medical applications, further broadening our pipeline and potential for out-licensing opportunities.
http://02c390e.netsolhost.com/invest.htm
Ah, you deleted my message. In Europe we call this censoring.
I received this email from Tom Fox:
"Dear xxxx,
Please allow me to introduce myself. My name is Tom Fox. I am the primary contact for The Amstem Corporation at Hawk Associates, Amstem's investor relations firm. I was forwarded your email by the company regarding the 10-K. The company will be issuing guidance regarding the status of their filings at the beginning of the week. In the meantime, if you should like to speak directly to me, please forward your contact number and I would be more than happy to call you. Thank you for your concerns and support. All the best."
Update:SteMixx consumer study is full and underway.
"The maximum number of participants have been enrolled for a 1-month trial and consumer study of SteMixx, AmStem's new professional, topical (non-injectable) facial cream."
http://amsteminc.com/index.php?option=com_content&view=article&id=80
Only one idiot bought at 0.0069 dollar/share. Probably the same idiot who bought a couple of days ago at 0.0070. He/she is hoping that others will follow, but they don't. Besides look at the buy volume of that idiot, it's pathetically small.
Technical summary from seekingalpha:
CTSO engineers are really great minds: read:
"The article focuses more in general on the potential of size exclusion chromatography such as gel electophoresis for example as analytical tool to determine properties of different substances and as a seperation technique. Cytosorb works with the same principle by controlling the concentration of the polimer beads within the cartridge.thus allowing for different size of the pores so certain of the substances within the blood which flows through the cartridge will delay and wouldn't enough for themto exit and pump back into the patient.
One point to mention related to the article is that this separation is done not entirely by site or weight but the shape of the proteins as well.(although most of the protein in the blood are globulins which are round shaped like.
But if for exmaple we would like to separate diffrent DNA/RNA molecules(gel elctrophoresis) the shape of the DNA(such as supercoiled,coiled,linear... depends also if it's in relax/tension condition and so on... will not get into it) will determine it's mobility in the stationary phase.
Anyway size exclusion chromatography is used with a wide variety of implementations and very powerful. this subject coudn't be covered with even an entire book and require alot of background information and experience in the lab."
quote from memeil26 yahoo message board 30-jun-2010
http://seekingalpha.com/instablog/399559-chemistfrog/78833-cytosorb-is-a-novel-application-of-tried-and-true-technology
I like this article's part best:
"However, it appears, the CytoSorb technology has the compactness of the aforementioned SPE cartridges and the particle size differentiation of GPC or size exclusion chromatography. These are very robust technologies utilized elsewhere for other applications on an everyday basis, and the great minds at Cytosorbents have a truly profound application that may soon revolutionize the medical field. It has the potential to save millions of lives every year due to the cytokine storms or severe sepsis caused by a myriad of infections, most notably all types of flu. In the future, it can also perhaps be used to filter out other discreet particle size or molecular weight compounds such as drugs. "
"If or when a flu pandemic whether H1N1, Avian or other unknown type hits; this will be another weapon in the world’s arsenal against a killer of potentially millions."
http://seekingalpha.com/instablog/399559-chemistfrog/78833-cytosorb-is-a-novel-application-of-tried-and-true-technology
Okay, that is bad! I will wait to get in, because I expect a big drop first.
@moderator: could you please sticky my last post?